|Bid||62.13 x 200|
|Ask||95.83 x 100|
|Day's Range||92.66 - 95.02|
|52 Week Range||78.42 - 100.51|
|PE Ratio (TTM)||-88.41|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||111.57|
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.
These three orphan drugmakers were on Soros' radar last quarter.